Systemic Therapies in Dermatology

Dermatology focuses on diagnosing and treating skin disorders. Systemic therapies refer to treatments that affect the entire body, typically administered orally or through injection rather than topical applications. These therapies have transformed the management of moderate to severe or resistant skin conditions.

Types of Systemic Therapies

Immunosuppressants and Immunomodulators

• Corticosteroids: Anti-inflammatory agents in oral and injectable forms for severe eczema, psoriasis, and autoimmune skin disorders.
• Methotrexate: A disease-modifying antirheumatic drug that suppresses the immune system and reduces skin cell turnover for severe psoriasis.
• Cyclosporine: An immunosuppressant used in severe psoriasis and eczema cases to reduce inflammation and immune response.

Biologic Therapies

Biologic therapies are treatments using substances made from living organisms:

• TNF-alpha Inhibitors (etanercept, adalimumab): Target inflammation molecules for moderate to severe psoriasis and hidradenitis suppurativa.
• IL-17 Inhibitors (secukinumab, ixekizumab): Target interleukin-17, a key cytokine in psoriasis inflammation, administered via injections or infusions.
• IL-23 Inhibitors (guselkumab, risankizumab): Target interleukin-23, crucial in psoriasis pathology and immune response.

Antibiotics and Antifungals

• Oral Antibiotics: Prescribed for bacterial infections like acne and folliculitis, inhibiting bacterial protein synthesis. Side effects include gastrointestinal disturbances and increased sun sensitivity.
• Antifungal Agents (itraconazole, fluconazole): Treat fungal skin infections including dermatophyte infections and candidiasis, administered orally in tablet or liquid form.

Retinoids

Retinoids are medications chemically derived from vitamin A that regulate numerous transcription factors:

• Isotretinoin: Treats moderate to severe acne unresponsive to other treatments by reducing sebum production and preventing acne formation.

Applications and Clinical Considerations

Dermatologists carefully evaluate patients to determine appropriate systemic treatment, considering:

• Disease Severity: Systemic therapies are reserved for moderate to severe cases not responding to topical treatments.
• Safety Profile: Each therapy carries potential risks and side effects requiring careful weighing of benefits against risks, regular patient monitoring, and education.
• Patient Characteristics: Age, medical history, concurrent medications, and pregnancy status influence selection and dosage.

Advancements and Emerging Trends

• Targeted Therapies: Biologics targeting specific immune molecules improve treatment outcomes for psoriasis and eczema with minimal systemic side effects compared to older immunosuppressants.
• Personalized Medicine: Genetic and biomarker research enables tailored treatments based on individual patient genetics and disease biomarkers, optimizing effectiveness.
• Combination Therapies: Integration of systemic treatments with topical medications or phototherapy enhances therapeutic benefits and potentially reduces treatment duration.
• Patient-Centered Care: Growing focus on patient-reported outcomes and quality-of-life assessments promotes development of therapies alleviating symptoms while enhancing overall well-being and satisfaction.

Challenges and Future Directions

• Cost and Accessibility: Biologics and newer systemic therapies remain costly, limiting accessibility for some patients.
• Long-Term Safety: Essential long-term safety data is needed, particularly for newer biologics, to understand immune function impacts and potential rare adverse events.
• Resistance and Non-Response: Some patients may not respond adequately or develop resistance over time, requiring alternative treatment strategies.

Conclusion

Systemic therapies represent a cornerstone of modern dermatological practice, offering effective solutions for patients with moderate to severe skin disorders. From immunosuppressants and biologics to retinoids and antimicrobials, these therapies continue evolving through scientific advances and clinical research. The future holds significant potential for innovation and improved patient outcomes in systemic dermatology therapies.